At ASHG, Illumina launches 5-base and shows exciting results from constellation, a breakthrough technology offering long-range genomic insights from unfragmented DNA.
Tech-savvy parents to be are using IVF and screening embryos to build families in ways that were unimaginable a few short years ago.
Next Generation Sequencing (NGS) Market Poised to Hit $42.25 Billion by 2033: Key Drivers Behind the Surge - Latest Study by Grand View Research, Inc.
Gene Fusion Testing Market to reach USD 2.5 Bn by 2035 at 12.1% CAGR, driven by rising cancer incidence and demand for ...
This growth is primarily driven by the rising global cancer incidence, increasing preference for non-invasive diagnostic ...
Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.
Where do the greatest opportunities for collaboration across life sciences disciplines lie today – and what’s needed to ...
Illumina exhibits better profitability ratios than many of its peers, which indicates that the company could continue to invest in its operations. In Q3 2025, ILMN raised its EPS to $4.65-$4.75, ...
Study shows that rare variants captured by Illumina WGS with DRAGEN™ variant calling explain most of the "missing heritability" in complex human diseases and traits, including those related to blood ...
SAN DIEGO - Illumina, Inc. (NASDAQ:ILMN) and University of Queensland researchers have published findings in Nature demonstrating that whole-genome sequencing (WGS) can explain nearly 90% of the ...
Cornell (NY, USA) researchers have found that a new DNA sequencing technology can be used to study how transposons move ...
Revenue: $1.08 billion, roughly flat year-over-year, exceeded guidance range. Non-GAAP Operating Margin: 24.5%, expanded by 190 basis points year-over-year. Non-GAAP Diluted EPS: $1.34, grew $0.20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback